Causes of hospitalization and death in the MANIF 2000 cohort, composed of HIV-infected patients contaminated by intravenous drug use, 1995-1999;Motifs d'hospitalisation et mortalité dans la cohorte MANIF 2000 composée de sujets infectés par le VIH et contaminés par usage de drogues en intraveineux, 1995-1999

Presse Medicale

Volumn 32, Issue 13 I, 2003, Pages 587-594

  Marimoutou, Catherine ^a,b,e   Poizot Martin, I ^c   Loundou, A D ^a,b   Cassuto, J P ^d   Obadia, Y ^a,b  

^a INSERM   (France)

^b Observ Regn S P Alpes Cote Azur   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DRUG ABUSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; VIRAL LOAD;

EID: 0344837788     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lot F, Pillonel J, Cazein F, Gouezel P, Laporte A. Diminution brutale du nombre de cas de sida-Rôle des nouvelles stratégies thérapeutiques? Bull Epidemiol Hebd 1997 (11): 43-5.
2. Mouton Y, Alfandari S, Valette M. et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 french AIDS reference centres. AIDS 1997; 11: F101-5.
3. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F for the Groupe d'Epidemiologie Clinique du sida en Aquitaine (GECSA). Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 358-64.
4. Cazein F, Pinget R, Lot F, David D, Pillonel J, Laporte A. Tendances récentes du sida en France, janvier 1998-juin 2000. Bull Epidemiol Hebd 2000 (52): 1-7.
5. Shapiro M, Morton S, McCaffrey D et al. Variations in the care of HIV-Infected adults in the United States: Results from the HIV cost and services utilization study. JAMA 1999; 281: 2305-15.
6. Kupek E, Dooley M, Whitaker L, Petrou S, Renton A. Demographic and socio-economic determinants of community and hospital services costs for people with HIV/AIDS in London. Social Science Med 1999; 48: 1433-40.
7. Mientjes G, van Ameijden E, van den Hoek A, Coutinho R. Increasing morbidity without rise in non-AIDS mortalily among HIV-infected intraveinous drug users in Amsterdam. AIDS 1992; 6: 207-12.
8. Van Haastrecht H, van den Hoek A, Coutinho R. High mortality among HIV-infected injecting drug users without AIDS diagnosis: implication for HIV infection epidemic modellers? AIDS 1994; 8: 363-6.
9. Laurichesse H, Mortimer J, Evans B, Farrington C. Pre-AIDS mortality in HIV-infected individuals in England, Wales and Northern Ireland, 1982-1996. AIDS 1998; 12: 651-8.
10. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11: F101-5.
11. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F for the GECSA. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995 to 1997. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18: 358-64.
12. Allardice GM, McMenamin JJ, Parpia T, Gibbs J, McSharry C, Whitelaw J. The recent impact of antiretroviral combination therapy on CD4 counts, AIDS and death in HIV-infected persons: routine HIV surveillance in Scotland. Int J STD AIDS 1998; 9: 561-6.
13. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
14. Aalen OO, Farewell VT, DeAngelis D, Day NE, Gill ON. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. AIDS 1999; 13: 103-8.
15. Van Haastrecht H, van Ameijden E, van den Hoek J, Mientjes G, Bax J, Coutinho R. Predictors of mortality in the Amsterdam cohort of Human Immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996; 143: 380-91.
16. Eskild A, Magnus P, Samuelsen S, Sohlberg C and Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. International J Epidemiol 1993; 22: 315-20.
17. Van Ameijden, Krol A, Vlahov D, Flynn C, van Haastrecht H, Coutinho R. Pre-AIDS mortality and morbidity among injection drug users in Amsterdam and Baltimore: an ecological comparison. Subst use Misuse 1999; 34: 845-65.
18. Van Ameijden E, Langendam M, Coutinho R. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addictive behaviors 1999; 24: 559-63.
19. Lepere B, Gourarier L, Sanchez M, et al. Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments. Ann Med Interne 2001; 152 suppl 3: 155-12.
20. Vandentorren S, Mercié P, Marimoutou C, Neau D, Malvy D, Farbos S, Dabis F. Trends in causes of death in Aquitaine Cohort of HIV-infected patients, 1995-1997. Eur J Epidemiol 2001; 17: 7-10.
21. Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndrome 2000; 24: 211-7.
22. Soto B, Sanchez-Quijano A, Rodriguo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterraly-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
23. Pol S, Fontaine H, Carnot F et al. The natural history of parenterrally-acquired chronic hepatitis C. J Hepatol 1998; 29: 12-20.
24. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-5.
25. Penzak SR, Reddy YS, Grimsley SR. Depression in patients with HIV infection. Am J Health-System pharmacy 2000; 57: 376-86.
26. Johnson JG, Rabkin JG, Lipsitz JD, Williams JB, Remien RH. Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Comprehensive Psychiatry 1999; 40: 31-4.
27. Sherbourne CD, Hays RD, Fleishman JA et al. Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry 2000; 157: 248-54.
28. Moatti JP, Carrieri Mp, Spire B, Gastaud JA, Cassuto JP, Moreau J and the Manif 2000 study group. Adherence to HAART in French HIV-infected injecting drug users: the contribution of Buprenorphine drug maintenance treatment. AIDS 2000; 14: 151-5.
29. Duran S, Spire B, Raffi F et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trails 2001; 2: 38-45.
30. Carrieri P, Cailleton CV, Lemoing V et al. The dynamic of adherence to Highly Active Antiretroviral Therapy: results from the French national APROCO cohort. J Acquir Immune Syndr 2001; 28: 232-9.
31. Thélot 8, Pialoux G, Delhommeau A, Piroth L, Salmon-Céron D et l'APPIT. Epidémiologie hospitalière des patients infectés par le VIH et le VHC. Bull Epidemiol Hebd 2000; (39): 171-3.
32. Kalichmann SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS patients care and STDS 2002; 16: 233-40.